China Agency Cuts Prices Of Cancer, Other Major Drugs By Average 17%
This article was originally published in PharmAsia News
China's planning agency said that as of Oct. 8, the price caps of more than 200 drug formulations, including those for treating cancer and the immune and blood systems, would be lowered by an average of 17%.
You may also be interested in...
Avadim Health argues National Advertising Division expects substantiation for its homeopathic topical claims at the same level FDA requires for NDAs. NAD also said although FTC’s competent, reliable scientific evidence standard is “flexible” to some degree, pain claims are held to a more rigid standard.
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.
The FDA has asked the company for more information to support its PoNS therapy for multiple sclerosis patients with gait deficit, including an additional analysis of clinical data and labeling modifications.